Page 7 - Chunhua Lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hainan provinceUnited statesHong kongUnited kingdomHong kong special administrative regionHong kong generalJasmine cuiMorphosys incyteChunhua luInnocare pharmaXencor incDrug administrationProducts administration of hainan provinceChina national medical products administrationDepartment of healthEuropean medicines agency

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongXiaoman liuKeymed biosciencesJasmine cuiChunhua luInnocare pharmaTiannuojiancheng pharmaBo chenChina national medical products administrationCare pharmaInvestigational new drugNational medical products administration

InnoCare Releases 2022 Mid-Year Results and Business Highlights

InnoCare Releases 2022 Mid-Year Results and Business Highlights
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongMacau generalKeymed biosciencesJasmine cuiChunhua luInnocare pharmaBureau of economyAmerican society of clinical oncologyCommission of developmentOther corporate developmentGovernment agencyChina national medical products administrationChina securities regulatory commissionInformation technologyChina national reimbursement drug list

InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesHong kongJasmine cuiJun zhuChunhua luInnocare pharmaChina national medical products administrationNational reimbursement drugDrug administrationCare pharmaDrug evaluationNew drug applicationMarginal zone lymphomaBeijing cancer hospitalBreakthrough therapy designationMultiple sclerosis

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongJasmine cuiInnocare pharmaChunhua luAmerican autoimmune related diseases associationCare pharmaAutoimmune related diseases associationPsoriasis diagnosisBlue book